Valuation: Shanghai Rightongene Biotechnology Co., Ltd.

Market Cap 1.24B 185M 164M 152M 139M 261M 17.54B 266M 1.83B 718M 9.15B 694M 679M 29.18B P/E 2024
-65.9x
P/E 2025 -29x
Enterprise Value 1.01B 152M 135M 125M 114M 214M 14.39B 218M 1.5B 589M 7.51B 569M 557M 23.93B EV / Sales 2024
3.33x
EV / Sales 2025 6.95x
Free-Float
62.91%
Yield 2024 *
-
Yield 2025 0.65%
08-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
04-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
16/10/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
08/09/25 Shanghai Rightongene Biotechnology's boards elects chairman RE
28/08/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
24/04/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
27/02/25 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25/02/25 Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies MT
19/02/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
17/02/25 Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback announced on February 29, 2024, has closed with 669,621 shares, representing 1.2% for CNY 17.02 million. CI
02/01/25 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
29/10/24 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
1 day+1.63%
1 week-9.75%
Current month-12.63%
1 month-2.69%
3 months-2.23%
6 months-21.67%
Current year-14.95%
1 week 22
Extreme 22
25.17
1 month 22
Extreme 22
27
Current year 17.81
Extreme 17.81
33.27
1 year 17.81
Extreme 17.81
33.27
3 years 12.38
Extreme 12.38
43.05
5 years 12.38
Extreme 12.38
86.39
10 years 12.38
Extreme 12.38
133.67
Manager TitleAgeSince
Chief Executive Officer 69 21/07/2024
Director of Finance/CFO 34 26/01/2025
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 53 23/08/2023
Chairman 69 21/07/2024
Director/Board Member 41 12/05/2019
Change 5-day change 1-year change 3-year change Capi.($)
+1.63%-9.75%-18.80%-40.02% 185M
+0.20%+5.31%-17.82%+13.79% 181B
-0.73%+7.09%-0.31%+32.06% 116B
+0.49%+6.25%-20.20%+11.58% 113B
+3.83%+5.50%-44.18%-6.77% 79.83B
-0.14%+5.27%+6.74%+82.45% 65.06B
+2.79%+2.37%+15.93%+68.64% 54.35B
-1.04%+4.35%+3.50%-26.18% 52.23B
+2.41%+8.18%-12.08%+30.45% 44.15B
-1.90%+2.29%+29.72%+8.98% 32.47B
Average +0.83%+4.03%-5.75%+17.50% 73.88B
Weighted average by Cap. +0.62%+5.59%-9.70%+22.12%

Financials

2024 2025
Net sales 242M 36.21M 32.19M 29.84M 27.15M 51.22M 3.44B 52.04M 359M 141M 1.79B 136M 133M 5.72B 177M 26.49M 23.55M 21.83M 19.86M 37.47M 2.51B 38.07M 262M 103M 1.31B 99.42M 97.31M 4.18B
Net income -15.76M -2.36M -2.09M -1.94M -1.77M -3.33M -224M -3.39M -23.33M -9.15M -117M -8.84M -8.65M -372M -50.38M -7.53M -6.69M -6.2M -5.64M -10.65M -715M -10.82M -74.56M -29.23M -373M -28.26M -27.65M -1.19B
Net Debt -210M -31.43M -27.94M -25.89M -23.56M -44.46M -2.98B -45.17M -311M -122M -1.56B -118M -115M -4.96B -222M -33.25M -29.55M -27.39M -24.92M -47.03M -3.16B -47.78M -329M -129M -1.65B -125M -122M -5.25B
Projected Income Statement - Annual - Shanghai Rightongene Biotechnology Co., Ltd.
Logo Shanghai Rightongene Biotechnology Co., Ltd.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production, sales, scientific research, and testing services of in vitro diagnostic products. The Company mainly provides self-branded molecular diagnostic reagents, scientific research services, testing services, and molecular testing equipment. The Company's main products are molecular diagnostic kits for leukemia, lymphoma, solid tumors, and infectious disease related genes. The Company's main services include providing third-party medical testing services for various medical institutions, pharmaceutical companies, individual patients, and others, as well as providing genetic testing research services for research hospitals, pharmaceutical companies, scientific research institutions, third-party testing institutions and other enterprises and institutions.
Employees
327
Date Price Change Volume
16/10/26 CN¥22.41 +1.63% 1,047,403
15/10/26 CN¥22.05 -3.63% 1,077,261
14/10/26 CN¥22.88 -5.38% 1,347,962
13/10/26 CN¥24.18 0.00% 1,374,263
12/10/26 CN¥24.18 -2.62% 1,119,922

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Shanghai Rightongene Biotechnology Co., Ltd.
  1. Stock Market
  2. Stocks
  3. 688217 Stock